Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
19,667
Total Claims
$5.4M
Drug Cost
263
Beneficiaries
$21K
Cost/Patient
Risk Score Breakdown 38/100
Score components are additive. Read full methodology
Peer Comparison vs. 218,535 Nurse Practitioner providers
-69%
Opioid rate vs peers
1.2% vs 3.8% avg
+1662%
Cost per patient vs peers
$21K vs $1,174 avg
+181%
Brand preference vs peers
24.9% vs 8.9% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 1662% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
1.2%
Opioid Rate
231
Opioid Claims
$1,482
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 4,877 claims · $2.9M
Generic: 14,707 claims · $2.6M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Omeprazole/Sodium Bicarbonate | 438 | $1.0M |
| Metformin Hcl | 136 | $432K |
| Semaglutide | 331 | $342K |
| Lipase/Protease/Amylase | 338 | $288K |
| Diclofenac Sodium | 304 | $193K |
| Linaclotide | 332 | $188K |
| Evolocumab | 301 | $182K |
| Dihydroergotamine Mesylate | 54 | $174K |
| Tirzepatide | 139 | $154K |
| Icosapent Ethyl | 346 | $138K |
| Diclofenac Epolamine | 245 | $135K |
| Apixaban | 137 | $85K |
| Adalimumab | 11 | $82K |
| Sitagliptin Phos/Metformin Hcl | 136 | $81K |
| Meloxicam, Submicronized | 93 | $76K |
Prescribing Profile
Patient Profile
75
Avg Age
64%
Female
1.51
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About